Search results
Biomarkers identified for successful treatment of bone marrow tumors
Medical Xpress· 6 days agoCAR T cell therapy has proven effective in treating various hematological cancers. In a clinical study, researchers from the University of Leipzig Medical Center and the Fraunhofer Institute ...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOX 59 Indianapolis· 14 hours agoKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate ...
Lorna Kay Collins
The Ponca City News· 5 days agoMercer, aged 69, passed away on April. Born on January 29, 1955, Lorna touched the lives of those around her with her strength, resilience, and...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 6 days agoEU Expands J&J’s Carvykti Label in Multiple Myeloma: The EC granted label expansion to J&J’s...
GoFundMe Launched to Support Memorial Costs for Nick Daniels III
Jambands.com· 2 days agoA GoFundMe page has been established in the wake of funk maestro and esteemed New Orleans bassist...
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
GuruFocus.com via Yahoo Finance· 6 days agoThe stark contrast in financial performance sets the stage for a detailed SWOT analysis to...
Could Vitamin D Help Fight Cancer?
Mercola· 1 day agoIn this way, vitamin D acts like a brake on the process of cell growth in many tissues of the body, helping to control the speed at which cells multiply. This is particularly important when ...
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 7 days agoBristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus...
StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)
ETF DAILY NEWS· 2 days agoStockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report published on Saturday. The firm issued a sell rating on the biotechnology company’s stock. Cellectis ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days ago- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism Data of BeyondSpring’s Lead Asset Plinabulin
